For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200430:nRSd3144La
RNS Number : 3144L Impact Healthcare REIT PLC 30 April 2020
30 April 2020
Impact Healthcare REIT plc
(the "Company")
DISCLOSURE OF RIGHTS ATTACHED TO EQUITY SHARES
In compliance with Listing Rule 9.2.6ER(1), the Company has forwarded to the
FCA a copy of its current Articles of Association, which is the document that
sets out the terms and conditions attaching to its listed equity shares. A
copy of the Articles of Association has been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://protect.mimecast-offshore.com/s/WpeFC2vNkrTp2yvOi1XUg5?domain=data.fca.org.uk)
FOR FURTHER INFORMATION, PLEASE CONTACT:
Impact Health Partners LLP via Maitland/AMO
Mahesh Patel
Andrew Cowley
Winterflood Securities Limited Tel: 020 3100 0000
Joe Winkley
Neil Langford
RBC Capital Markets Tel: 020 7653 4000
Rupert Walford
Matthew Coakes
Maitland/AMO (Communications Adviser) Tel: 020 7379 5151
James Benjamin Email: impacthealth-maitland@maitland.co.uk
The Company's LEI is 213800AX3FHPMJL4IJ53.
Further information on Impact Healthcare REIT is available at
www.impactreit.uk (http://www.impactreit.uk/) .
NOTES:
Impact Healthcare REIT plc is a real estate investment trust ("REIT") which
aims to provide shareholders with an attractive return, principally in the
form of quarterly income distributions and with the potential for capital and
income growth, through exposure to a diversified portfolio of UK healthcare
real estate opportunities, in particular care homes for the elderly. The
Group's investment policy is to acquire, renovate, extend and redevelop high
quality healthcare real estate assets in the UK and lease those assets
primarily to healthcare operators providing residential healthcare services
under full repairing and insuring leases.
The Group's Ordinary Shares were admitted to trading on the main market of the
London Stock Exchange, premium segment, on 8 February 2019. The Company is a
constituent of the FTSE EPRA/NAREIT index.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
. END CIRSEMSUUESSELL